Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Knowles Corporation (KN) SEC Filings & Earnings Calls

EquiReason read 10 Knowles Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Q3 revenue $184M beat guidance high end, up 20% YoY; book-to-bill >1 for 8th quarter; FY26 revenue guided ~$689M (+16% YoY); Q4 revenue guided $180-190M; non-GAAP EPS $0.38 at high.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

KNKnowles CorporationFollow KN — free
Electronic Components · Technology
—
Price chart with a free account
Market cap
2.7B
P/E TTM
41.8
Dividend yield
—
52-week
—
Next earnings
3 Feb, in 102 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

22 Oct 20268-K · 2.02Q3 revenue $184M beat guidance high end, up 20% YoY; book-to-bill >1 for 8th quarter; FY26 revenue guided ~$689M (+16% YoY); Q4 revenue guided $180-190M; non-GAAP EPS $0.38 at high end of range; strong demand in medtech/defense/industrial/eearningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2026$184M+20% y/y
Non-GAAP gross profit · Q3-2026$83M+18% y/y
Non-GAAP gross margin · Q3-202645.3%
GAAP diluted EPS · Q3-2026$0.24+14% y/y
Non-GAAP diluted EPS · Q3-2026$0.38+15% y/y
Net cash from operations · Q3-2026$45M+53% y/y

Guidance

Q4 2026 revenue $180-190M; Q4 non-GAAP diluted EPS $0.39-0.43; Q4 net cash from operations $60-70M; FY26 revenue ~$689M (+16% YoY)

Q3 revenue beat high end of guidance; Q4 guidance implies continued growth; management expects to exceed Investor Day targets in 2027.

Risks flagged

Gross margin compression despite revenue growth; GAAP gross margin down 150 bps YoY, non-GAAP down 90 bps.

“GAAP gross margin 44.2% vs 45.7% YoY; non-GAAP 45.3% vs 46.2% YoY”
Read the original on SEC EDGAR ↗
28 Jul 202610-QKnowles reported strong Q2 2026 results: revenue +14.3% YoY, GAAP gross margin +320bps, Adjusted EBIT margin +260bps, and non-GAAP EPS +37.5% YoY.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$167M+14% y/y
Non-GAAP gross profit margin · Q2-202645.4%
Adjusted EBIT margin · Q2-202621.6%
Non-GAAP diluted EPS · Q2-2026$0.33+38% y/y
PD segment revenue · Precision Devices · Q2-2026$98M+25% y/y
MSA segment revenue · MedTech & Specialty Audio · Q2-2026$69M+2% y/y
Net earnings from continuing operations · Q2-2026$18M+136% y/y
Adjusted free cash flow · H1-2026$20M-66% y/y

Risks flagged

Tariff uncertainty

“The tariff environment remains highly dynamic. On February 20, 2026, a Supreme Court ruling invalidated certain tariffs previously imposed under the International Emergency Economic Powers Act ("IEEPA"). Knowles submitted refund requests and has, to date, received a portion of previously paid IEEPA tariffs. However, as a relatively small percentage of our pr” · word for word

Production transfer costs

“This increase was primarily due to higher shipping volumes, unfavorable product mix, and increased production transfer costs in our ceramic capacitor business.” · word for word
Read the original on SEC EDGAR ↗
23 Jul 20268-K · 2.02Revenues $167M (+14% y/y); Non-GAAP Gross Profit $76M (+17% y/y); Non-GAAP Gross Margin 45.4; Guidance: 2026 revenue growth raised to 10-12% from prior; adjusted EBITDA growth >20%earningsopen

Figures in the filing · each found in the filing text

Revenues · Q2-2026$167M+14% y/y
Non-GAAP Gross Profit · Q2-2026$76M+17% y/y
Non-GAAP Gross Margin · Q2-202645.4%
Non-GAAP Diluted EPS · Q2-2026$0.33+38% y/y
Net Cash Provided by Operating Activities · Q2-2026$28M-23% y/y

Guidance

2026 revenue growth raised to 10-12% from prior; adjusted EBITDA growth >20%

Revenue and EPS beat; guidance raised on strong bookings and design wins; management confident in exceeding organic growth targets.

Risks flagged

Dependence on specialty electronic components market; cyclical demand in industrial and defense.

“Exposure to medtech, defense, industrial, and electrification markets; potential cyclicality.”
Read the original on SEC EDGAR ↗
28 Apr 202610-QRevenue $153M (+16% y/y); Gross profit $67M (+26% y/y); Gross profit margin 43.8; Guidance: Capex expected 4% to 5% of revenuesopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$153M+16% y/y
Gross profit · Q1-2026$67M+26% y/y
Gross profit margin · Q1-202643.8%
Non-GAAP gross profit · Q1-2026$70M+27% y/y
Non-GAAP gross profit margin · Q1-202645.5%
Adjusted EBIT · Q1-2026$30M+39% y/y
Adjusted EBIT margin · Q1-202619.7%
Non-GAAP diluted EPS · Q1-2026$0.27+50% y/y
PD segment revenue · Precision Devices · Q1-2026$85M+17% y/y
MSA segment revenue · MedTech & Specialty Audio · Q1-2026$68M+14% y/y

Guidance

Capex expected 4% to 5% of revenues

Revenue growth of 15.8% YoY, margin expansion, and capex increase for capacity expansion indicate positive outlook.

Risks flagged

Tariff uncertainty and potential input cost pressure

“Knowles has historically paid IEEPA duties, and we are currently pursuing the opportunity for potential tariff refunds. However, the amount and timing of any potential recovery is uncertain.” · word for word

Foreign currency exchange rate risk

“Other expense for the first quarter of 2026 was $3.4 million, compared with expense of $0.5 million for the first quarter of 2025, a change of $2.9 million. Expense in 2026 is primarily due to unfavorable foreign currency exchange rate changes.” · word for word
Read the original on SEC EDGAR ↗
23 Apr 20268-K · 2.02Revenue $153M (+16% y/y); Non-GAAP Diluted EPS from Continuing Operations $0.27 (+50% y/y); Gross Profit $67M; Guidance: above high-end of annual growth targetsearningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$153M+16% y/y
Non-GAAP Diluted EPS from Continuing Operations · Q1-2026$0.27+50% y/y
Gross Profit · Q1-2026$67M
Non-GAAP Gross Profit · Q1-2026$70M

Guidance

above high-end of annual growth targets

Expects organic revenue and adjusted EBITDA growth above annual targets.

Read the original on SEC EDGAR ↗
11 Mar 2026DEF 14AProxy statement filed for 2026 annual meeting, disclosing executive compensation structure and 2025 financial results.open

Figures in the filing · each found in the filing text

Revenue · FY2025$593M+7% y/y
Adjusted EBIT · FY2025$120M+11% y/y
Adjusted EBIT Margin · FY202520.2%
Net cash provided by operating activities · FY2025$114M-12% y/y
Adjusted Free Cash Flow · FY2025$114M+22% y/y
Net Income · FY2025$51M

Risks flagged

CD Business Underperformance

“CD Business Unit Performance ... Revenue ($M) ... Actual results $123.8 ... Results as a % of Target 60.0%”

CEO Financial PSU Award Dilution Risk

“The CEO Financial PSU Award has a grant date fair value of $1.5 million. ... maximum payout cap of 400%.” · word for word
Read the original on SEC EDGAR ↗
20 Feb 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportSEC ↗
9 Feb 202610-KRisks named: Supply Chain Disruption Risk, Trade Policy/Tariff Riskopen

Risks flagged

Customer Concentration Risk

“Our MSA segment... relies on a limited number of customers for a significant portion of their sales. For 2025, MSA's top five customers accounted for approximately 76% of its revenues.”

Supply Chain Disruption Risk

“Certain of our businesses rely on highly specialized suppliers or foundries for critical materials, components, or subassemblies that are used in our products. In some cases, our suppliers or foundries are our sole source of supply.” · word for word

Trade Policy/Tariff Risk

“Any unfavorable government policies on international trade, such as export and import controls, capital controls or tariffs, may affect the demand for our products and services, increase the cost of components, delay production.” · word for word
Read the original on SEC EDGAR ↗
5 Feb 20268-K · 2.02Revenues $162M (+14% y/y); Non-GAAP gross profit as a % of revenues 45.3; Non-GAAP diluted earnings per share $0.36; Guidance: Q1 2026 revenue guidance $143M-$153M, non-GAAP EPS $0.22-$0.26earningsopen

Figures in the filing · each found in the filing text

Revenues · continuing_operations · Q4-2025$162M+14% y/y
Non-GAAP gross profit as a % of revenues · Q4-202545.3%
Non-GAAP diluted earnings per share · Q4-2025$0.36
Net cash provided by operating activities · Q4-2025$47M

Guidance

Q1 2026 revenue guidance $143M-$153M, non-GAAP EPS $0.22-$0.26

Q1 2026 guidance implies continued growth with revenue midpoint of $148M (slightly below Q4 but seasonally normal) and non-GAAP EPS above prior year. CEO expressed confidence in strong revenue and earnings growth for 2026.

Read the original on SEC EDGAR ↗
28 Oct 202510-QKnowles reported Q3 2025 revenue of $152.9M, up 7.3% YoY, and net income of $17.4M, a significant improvement from $0.5M in Q3 2024.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$153M+7% y/y
Net earnings (loss) · Q3-2025$17M
Diluted EPS from continuing operations · Q3-2025$0.21
Gross profit · Q3-2025$70M+11% y/y
Operating cash flow · 9M-2025$67M-30% y/y
Free cash flow · 9M-2025$50M

Risks flagged

Restructuring execution risk

“Restructuring charges of $3.2 million during the nine months ended September 30, 2025, related to headcount reductions across the Company primarily to rightsize operating expenses subsequent to the sale of CMM.”

Cash burn from buybacks and debt

“Cash and cash equivalents decreased from $130.1 million at December 31, 2024 to $92.5 million at September 30, 2025, driven by $55.0 million in share repurchases and $30.0 million in debt repayments.”
Read the original on SEC EDGAR ↗

Knowles Corporation — questions

What did Knowles Corporation file recently?
10 SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Q3 revenue $184M beat guidance high end, up 20% YoY; book-to-bill >1 for 8th quarter; FY26 revenue guided ~$689M (+16% YoY); Q4 revenue guided $180-190M; non-GAAP EPS $0.38 at high end of range; strong demand in medtech/defense/industrial/e

Every figure on this page comes from Knowles Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.